Cargando…

Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis

Traditional atherosclerosis risk factors cannot elucidate the increased prevalence of cardiovascular events in end stage renal disease (ESRD) patients on hemodialysis. A previous study has indicated a strong association of the PI(A1/A2) polymorphism with myocardial infarction, diabetes and renal all...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Ali, Amein, Al-Muhanna, Fahad, Al-Mueilo, Samir, Larbi, Emmanuel, Al-Sultan, Ali, Rubaish, Abdullah, Al-Ateeq, Suad, Al-Zaharani, Alhusain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Master Publishing Group 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614702/
https://www.ncbi.nlm.nih.gov/pubmed/23675086
_version_ 1782264896636846080
author Al-Ali, Amein
Al-Muhanna, Fahad
Al-Mueilo, Samir
Larbi, Emmanuel
Al-Sultan, Ali
Rubaish, Abdullah
Al-Ateeq, Suad
Al-Zaharani, Alhusain
author_facet Al-Ali, Amein
Al-Muhanna, Fahad
Al-Mueilo, Samir
Larbi, Emmanuel
Al-Sultan, Ali
Rubaish, Abdullah
Al-Ateeq, Suad
Al-Zaharani, Alhusain
author_sort Al-Ali, Amein
collection PubMed
description Traditional atherosclerosis risk factors cannot elucidate the increased prevalence of cardiovascular events in end stage renal disease (ESRD) patients on hemodialysis. A previous study has indicated a strong association of the PI(A1/A2) polymorphism with myocardial infarction, diabetes and renal allograft rejection. In this investigation, we determined the prevalence of the PI(A1/A2) polymorphism of platelet glycoprotein (GP) IIb/IIIa in ESRD patients on hemodialysis in the Eastern Province of Saudi Arabia. The PI(A1/A2) polymorphism was determined in 42 ESRD patients receiving hemodialysis and in 49 subjects without current or past history of renal disease. Genotypes were determined by a reverse-hybridization assay and were confirmed by restriction fragment length polymorphism procedures. The PI(A2) allele frequency among the control sample was 28.6% (2 were homozygous for PI(A2), 23 were homozygous for PI(A1), and 24 were heterozygous PI(A1/A2)). The PI(A2) allele frequency among the hemodialysis sample was 50% (2 were homozygous for PI(A2), 2 were homozygous for PI(A1) and 38 were heterozygous for PI(A1/A2)). The PI(A2) allele frequency among the hemodialysis patients was significantly higher than that in the control group [Odds ratios 2.5 (1.35-4.61), p<0.003; Adjusted odds ratios of 2.21 (1.05-4.65), p<0.036 after adjustment for the presence of diabetes; Simultaneously adjusting the odds ratios for the presence of standard risk factors (diabetes and hypertension) gave an adjusted OR of 6.87 (1.54-30.71), p=0.064]. These results suggest that the PI(A2) polymorphism may contribute toward the etiology of cardiovascular diseases in ESRD patients. A further study with a larger sample size is needed to confirm above results.
format Online
Article
Text
id pubmed-3614702
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Master Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36147022013-05-01 Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis Al-Ali, Amein Al-Muhanna, Fahad Al-Mueilo, Samir Larbi, Emmanuel Al-Sultan, Ali Rubaish, Abdullah Al-Ateeq, Suad Al-Zaharani, Alhusain Int J Biomed Sci Article Traditional atherosclerosis risk factors cannot elucidate the increased prevalence of cardiovascular events in end stage renal disease (ESRD) patients on hemodialysis. A previous study has indicated a strong association of the PI(A1/A2) polymorphism with myocardial infarction, diabetes and renal allograft rejection. In this investigation, we determined the prevalence of the PI(A1/A2) polymorphism of platelet glycoprotein (GP) IIb/IIIa in ESRD patients on hemodialysis in the Eastern Province of Saudi Arabia. The PI(A1/A2) polymorphism was determined in 42 ESRD patients receiving hemodialysis and in 49 subjects without current or past history of renal disease. Genotypes were determined by a reverse-hybridization assay and were confirmed by restriction fragment length polymorphism procedures. The PI(A2) allele frequency among the control sample was 28.6% (2 were homozygous for PI(A2), 23 were homozygous for PI(A1), and 24 were heterozygous PI(A1/A2)). The PI(A2) allele frequency among the hemodialysis sample was 50% (2 were homozygous for PI(A2), 2 were homozygous for PI(A1) and 38 were heterozygous for PI(A1/A2)). The PI(A2) allele frequency among the hemodialysis patients was significantly higher than that in the control group [Odds ratios 2.5 (1.35-4.61), p<0.003; Adjusted odds ratios of 2.21 (1.05-4.65), p<0.036 after adjustment for the presence of diabetes; Simultaneously adjusting the odds ratios for the presence of standard risk factors (diabetes and hypertension) gave an adjusted OR of 6.87 (1.54-30.71), p=0.064]. These results suggest that the PI(A2) polymorphism may contribute toward the etiology of cardiovascular diseases in ESRD patients. A further study with a larger sample size is needed to confirm above results. Master Publishing Group 2008-09 /pmc/articles/PMC3614702/ /pubmed/23675086 Text en © Amein Al-Ali et al. Licensee Master Publishing Group http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Al-Ali, Amein
Al-Muhanna, Fahad
Al-Mueilo, Samir
Larbi, Emmanuel
Al-Sultan, Ali
Rubaish, Abdullah
Al-Ateeq, Suad
Al-Zaharani, Alhusain
Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis
title Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis
title_full Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis
title_fullStr Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis
title_full_unstemmed Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis
title_short Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis
title_sort increased prevalence of glycoprotein iib/iiia leu 33 pro polymorphism in end stage renal disease patients on hemodialysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614702/
https://www.ncbi.nlm.nih.gov/pubmed/23675086
work_keys_str_mv AT alaliamein increasedprevalenceofglycoproteiniibiiialeu33propolymorphisminendstagerenaldiseasepatientsonhemodialysis
AT almuhannafahad increasedprevalenceofglycoproteiniibiiialeu33propolymorphisminendstagerenaldiseasepatientsonhemodialysis
AT almueilosamir increasedprevalenceofglycoproteiniibiiialeu33propolymorphisminendstagerenaldiseasepatientsonhemodialysis
AT larbiemmanuel increasedprevalenceofglycoproteiniibiiialeu33propolymorphisminendstagerenaldiseasepatientsonhemodialysis
AT alsultanali increasedprevalenceofglycoproteiniibiiialeu33propolymorphisminendstagerenaldiseasepatientsonhemodialysis
AT rubaishabdullah increasedprevalenceofglycoproteiniibiiialeu33propolymorphisminendstagerenaldiseasepatientsonhemodialysis
AT alateeqsuad increasedprevalenceofglycoproteiniibiiialeu33propolymorphisminendstagerenaldiseasepatientsonhemodialysis
AT alzaharanialhusain increasedprevalenceofglycoproteiniibiiialeu33propolymorphisminendstagerenaldiseasepatientsonhemodialysis